Beta-containing COVID-19 booster vaccine found to cross-neutralize

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants, Journal of Biomedical Science

Obesity may weaken vaccine protection; unvaccinated Omicron patients face risk from variants

Frontiers SARS-CoV-2 Variants, Vaccines, and Host Immunity

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants

Dean Huang's Instagram, Twitter & Facebook on IDCrawl

COVID-19 model update: Omicron and waning immunity

Dean Huang's Instagram, Twitter & Facebook on IDCrawl

Alhydroxiquim-II-adjuvanted vaccines afford cross-species

Frontiers Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 - ScienceDirect

Current vaccines teach T cells to fight Omicron

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Vaccines, Free Full-Text